Loading...

Alcidion Group

ASX:ALC
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALC
ASX
A$134M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Alcidion Group Limited provides health informatics software in Australia and New Zealand. The last earnings update was 145 days ago. More info.


Add to Portfolio Compare Print
  • Alcidion Group has significant price volatility in the past 3 months.
ALC Share Price and Events
7 Day Returns
-2.9%
ASX:ALC
1.7%
AU Healthcare Services
-0.9%
AU Market
1 Year Returns
209.1%
ASX:ALC
137.6%
AU Healthcare Services
4.2%
AU Market
ALC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Alcidion Group (ALC) -2.9% 47.8% 188.1% 209.1% 385.7% -
AU Healthcare Services 1.7% 17.8% 63.2% 137.6% 90.7% 877.1%
AU Market -0.9% 1.4% 6% 4.2% 19% 11%
1 Year Return vs Industry and Market
  • ALC outperformed the Healthcare Services industry which returned 137.6% over the past year.
  • ALC outperformed the Market in Australia which returned 4.2% over the past year.
Price Volatility
ALC
Industry
5yr Volatility vs Market

Value

 Is Alcidion Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Alcidion Group. This is due to cash flow or dividend data being unavailable. The share price is A$0.17.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Alcidion Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Alcidion Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ALC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:ALC Share Price ** ASX (2019-07-19) in AUD A$0.17
Global Healthcare Services Industry PE Ratio Median Figure of 38 Publicly-Listed Healthcare Services Companies 37.87x
Australia Market PE Ratio Median Figure of 546 Publicly-Listed Companies 16.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Alcidion Group.

ASX:ALC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ALC Share Price ÷ EPS (both in AUD)

= 0.17 ÷ 0.00

-75.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alcidion Group is loss making, we can't compare its value to the Global Healthcare Services industry average.
  • Alcidion Group is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Alcidion Group's expected growth come at a high price?
Raw Data
ASX:ALC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -75.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Healthcare Services Industry PEG Ratio Median Figure of 25 Publicly-Listed Healthcare Services Companies 2.28x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Alcidion Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Alcidion Group's assets?
Raw Data
ASX:ALC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:ALC Share Price * ASX (2019-07-19) in AUD A$0.17
Australia Healthcare Services Industry PB Ratio Median Figure of 15 Publicly-Listed Healthcare Services Companies 5.13x
Australia Market PB Ratio Median Figure of 1,693 Publicly-Listed Companies 1.7x
ASX:ALC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ALC Share Price ÷ Book Value per Share (both in AUD)

= 0.17 ÷ 0.02

10.73x

* Primary Listing of Alcidion Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Alcidion Group is overvalued based on assets compared to the AU Healthcare Services industry average.
X
Value checks
We assess Alcidion Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Alcidion Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Alcidion Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alcidion Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.1%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Alcidion Group expected to grow at an attractive rate?
  • Unable to compare Alcidion Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Alcidion Group's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Alcidion Group's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:ALC Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 36.1%
Australia Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 31.1%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7.4%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ALC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ALC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 10 -1 -2
2018-09-30 7 -1 -2
2018-06-30 4 -2 -2
2018-03-31 4 -2 -2
2017-12-31 3 -1 -2
2017-09-30 3 -1 -2
2017-06-30 3 -1 -2
2017-03-31 4 -1 -3
2016-12-31 4 -2 -3
2016-09-30 4 -2 -3
2016-06-30 4 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Alcidion Group is high growth as no earnings estimate data is available.
  • Unable to determine if Alcidion Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ALC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Alcidion Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALC Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Alcidion Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Alcidion Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Alcidion Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Alcidion Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Alcidion Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Alcidion Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Alcidion Group's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Alcidion Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Alcidion Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Alcidion Group's 1-year growth to the Global Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Alcidion Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Alcidion Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 9.73 -1.60 5.31
2018-09-30 6.96 -1.84 4.70
2018-06-30 4.18 -2.09 4.08
2018-03-31 3.78 -1.82 3.73
2017-12-31 3.38 -1.56 3.37
2017-09-30 3.42 -1.81 3.65
2017-06-30 3.46 -2.06 3.93
2017-03-31 3.68 -2.60 3.96
2016-12-31 3.89 -3.14 4.00
2016-09-30 3.96 -2.84 3.69
2016-06-30 4.02 -2.54 3.38
2015-06-30 5.18 -0.32 3.03
2014-06-30 2.37 -1.44 0.53
2013-06-30 5.05 0.26 0.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Alcidion Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Alcidion Group has efficiently used its assets last year compared to the Global Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Alcidion Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Alcidion Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Alcidion Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Alcidion Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Alcidion Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Alcidion Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Alcidion Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Alcidion Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Alcidion Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Alcidion Group Company Filings, last reported 6 months ago.

ASX:ALC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 12.76 0.00 1.32
2018-09-30 12.76 0.00 1.32
2018-06-30 3.33 0.00 2.89
2018-03-31 3.33 0.00 2.89
2017-12-31 4.37 0.00 4.63
2017-09-30 4.37 0.00 4.63
2017-06-30 5.42 0.00 5.33
2017-03-31 5.42 0.00 5.33
2016-12-31 5.70 0.00 5.72
2016-09-30 5.70 0.00 5.72
2016-06-30 6.57 0.01 5.65
2015-06-30 0.65 1.55 2.32
2014-06-30
2013-06-30
  • Alcidion Group has no debt.
  • Alcidion Group currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Alcidion Group has less than a year of cash runway based on current free cash flow.
  • Alcidion Group has less than a year of cash runway if free cash flow continues to reduce at historical rates of -20.9% each year.
X
Financial health checks
We assess Alcidion Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Alcidion Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Alcidion Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Alcidion Group dividends.
If you bought A$2,000 of Alcidion Group shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Alcidion Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alcidion Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ALC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 1.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 415 Stocks 4.1%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Alcidion Group has not reported any payouts.
  • Unable to verify if Alcidion Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Alcidion Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Alcidion Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Alcidion Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Alcidion Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Alcidion Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Alcidion Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kate Quirke
TENURE AS CEO 1 years
CEO Bio

Ms. Kate Quirke has been Chief Executive Officer and Executive Director of Alcidion Group Ltd. since July 3, 2018. Ms. Quirke served as Chief Executive Officer of MKM Health. She is a highly experienced executive with deep expertise in the healthcare IT sector.

CEO Compensation
  • Insufficient data for Kate to compare compensation growth.
  • Insufficient data for Kate to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure

Average tenure of the Alcidion Group management team in years:

0.4
Average Tenure
  • The average tenure for the Alcidion Group management team is less than 2 years, this suggests a new team.
Management Team

Ray Blight

TITLE
Non-Executive Chairman
COMPENSATION
A$287K

Malcolm Pradhan

TITLE
Chief Medical Officer
COMPENSATION
A$269K

Kate Quirke

TITLE
CEO & Executive Director
TENURE
1 yrs

Colin MacKinnon

TITLE
CFO & COO
TENURE
0.4 yrs

Tracey Harvey

TITLE
Human Resources Manager

Kevin Moynihan

TITLE
Executive Vice President of Business Development
TENURE
1.6 yrs

Melanie Leydin

TITLE
Joint Company Secretary
TENURE
0.3 yrs

Michael Sapountzis

TITLE
Joint Company Secretary
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the Alcidion Group board of directors in years:

2.7
Average Tenure
  • The average tenure for the Alcidion Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ray Blight

TITLE
Non-Executive Chairman
COMPENSATION
A$287K
TENURE
3.4 yrs

Malcolm Pradhan

TITLE
Chief Medical Officer
COMPENSATION
A$269K
TENURE
3.4 yrs

Kate Quirke

TITLE
CEO & Executive Director
TENURE
1 yrs

Nick Dignam

TITLE
Non Executive Director
TENURE
3.4 yrs

Rebecca Wilson

TITLE
Independent Non-Executive Director
COMPENSATION
A$37K
TENURE
1.9 yrs

Katrina Dolye

TITLE
Director
TENURE
0.8 yrs

Simon Chamberlain

TITLE
Non-Executive Director
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Alcidion Group individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
29. Apr 19 Buy Rebecca Wilson Individual 29. Apr 19 29. Apr 19 110,000 A$0.08 A$9,130
29. Apr 19 Buy Katrina Dolye Individual 26. Apr 19 26. Apr 19 2,000,000 A$0.08 A$165,398
04. Apr 19 Buy Raymond Blight Individual 29. Nov 18 29. Nov 18 1,000,000 A$0.05 A$48,049
27. Mar 19 Sell Bspe Medical Technology Pty Ltd Company 20. Mar 19 27. Mar 19 -84,864,273 A$0.06 A$-3,997,531
03. Dec 18 Buy Katrina Dolye Individual 29. Nov 18 29. Nov 18 2,000,000 A$0.05 A$95,824
X
Management checks
We assess Alcidion Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Alcidion Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Are Alcidion Group Limited (ASX:ALC) Insiders Spending On Buying Shares?

Alcidion Group Insider Transactions Over The Last Year. … Over the last year, we can see that insiders have bought 8.12m shares worth AU$365k. … In total, Alcidion Group insiders bought more than they sold over the last year

Simply Wall St -

What Kind Of Investor Owns Most Of Alcidion Group Limited (ASX:ALC)?

The big shareholder groups in Alcidion Group Limited (ASX:ALC) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$31m, Alcidion Group is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Alcidion Group Limited (ASX:ALC) Insiders Increased Their Holdings

So shareholders might well want to know whether insiders have been buying or selling shares in Alcidion Group Limited (ASX:ALC). … The Last 12 Months Of Insider Transactions At Alcidion Group. … In the last twelve months there was more buying than selling by Alcidion Group insiders

Simply Wall St -

Is Alcidion Group Limited's (ASX:ALC) Balance Sheet A Threat To Its Future?

The direct benefit for Alcidion Group Limited (ASX:ALC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Does ALC's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Does Alcidion Group Limited (ASX:ALC) Need To Issue More Shares?

Given that Alcidion Group is spending more money than it earns, it will need to fund its expenses via external sources of capital. … ASX:ALC Income Statement May 16th 18 When will Alcidion Group need to raise more cash? … My cash burn analysis suggests that Alcidion Group has a cash runway of 1.3 years, given its current level of cash holdings.

Simply Wall St -

Is Alcidion Group Limited's (ASX:ALC) CEO Overpaid Relative To Its Peers?

Performance can be measured based on factors such as earnings and total shareholder return (TSR). … Usually I would look at market cap and earnings as a proxy for performance, however, ALC's negative earnings reduces the usefulness of my formula. … Next Steps: Hopefully this article has given you insight on how shareholders should think about ALC's governance policies such as CEO pay.

Simply Wall St -

What Does Alcidion Group Limited's (ASX:ALC) Ownership Structure Look Like?

Today, I will be analyzing Alcidion Group Limited’s (ASX:ALC) recent ownership structure, an important but not-so-popular subject among individual investors. … View our latest analysis for Alcidion Group ASX:ALC Ownership_summary Apr 6th 18 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: A relatively significant holding of company insiders could mean high alignment with shareholders.

Simply Wall St -

Want To Invest In Alcidion Group Limited (ASX:ALC)? Here's How It Performed Lately

In this article, I will take a look at Alcidion Group Limited's (ASX:ALC) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … See our latest analysis for Alcidion Group Did ALC beat its long-term earnings growth trend and its industry? … For Alcidion Group, its most recent trailing-twelve-month earnings is -AU$1.56M, which, in comparison to the prior year's level, has become less negative.

Simply Wall St -

What’s Ahead For Alcidion Group Limited (ASX:ALC)?

Below, I will examine the sector growth prospects, as well as evaluate whether Alcidion Group is lagging or leading its competitors in the industry. … See our latest analysis for Alcidion Group What’s the catalyst for Alcidion Group's sector growth? … Next Steps: Alcidion Group has been a healthcare tech industry laggard in the past year.

Simply Wall St -

Alcidion Group Limited's (ASX:ALC) EPS Grew 45.7% In A Year. Was It Better Than Long-Term Trend?

When Alcidion Group Limited (ASX:ALC) released its most recent earnings update (30 June 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … View our latest analysis for Alcidion Group How Did ALC's Recent Performance Stack Up Against Its Past? … Though Alcidion Group's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

Company Info

Description

Alcidion Group Limited provides health informatics software in Australia and New Zealand. The company offers Miya ED, which provides a set of clinical dashboards and ED whiteboards that allow emergency rooms to have a dedicated display for risk management; Miya Patient Flow that offers real-time patient journey and bed management solution for its hospital coordination, and risk and task management; Miya Revenue and Reimbursement, an enterprise analytics solution; and Smartpage, a secure healthcare messaging system that enables communication to enhance the coordination of care. It also provides Miya iScheduler, a suite of electronic referrals software that enhances the access of patients for hospital outpatient, ambulatory, and telehealth services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. The company is based in Wayville, Australia.

Details
Name: Alcidion Group Limited
ALC
Exchange: ASX
Founded:
A$133,760,737
810,671,138
Website: http://www.alcidion.com
Address: Alcidion Group Limited
40 Greenhill Road,
Level 2,
Wayville,
South Australia, 5034,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ALC Ordinary Shares Australian Securities Exchange AU AUD 01. Aug 2014
CHIA ALC Ordinary Shares Chi-X Australia AU AUD 01. Aug 2014
Number of employees
Current staff
Staff numbers
0
Alcidion Group employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 10:36
End of day share price update: 2019/07/19 00:00
Last earnings filing: 2019/02/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.